Literature DB >> 10814996

Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection.

M Witz1, J Lehmann, Z Korzets.   

Abstract

Thrombosis of upper extremity arteries is most commonly due to atherosclerosis of the proximal subclavian artery, trauma, or catheter-related injury. In the absence of an identifiable cause, a search for a hypercoagulable state is indicated. Hematologic manifestations of human immunodeficiency virus (HIV) infection and AIDS are frequent occurrences (Coyle TE. Med Clin N Am 1997;81:449-476). The most important of these are cytopenias (anemia, neutropenia, and thrombocytopenia). The incidence and severity of cytopenia are generally correlated to the stage of the HIV infection. In addition, various coagulation abnormalities have been reported in HIV-infected patients. Apart from thrombocytopenia, these have included a prolonged APTT due to the presence of lupus anticoagulant, an increased prevalence of protein S and heparin cofactor II deficiency, and hypoalbuminemia-related fibrin polymerization defects (Toulon P. Ann Bio Clin (Paris) 1998;56:153-160). HIV infection has also been associated with endothelial dysfunction. Although for the most part asymptomatic, elevated D-dimer levels have been found in HIV-infected patients, suggesting the existence of a prethrombotic state. In fact, clinical thrombosis eventuates in 2% of these patients (Toulon, 1988). Documented thromboses have involved both veins and arteries. We hereby present a patient who developed an acute thrombosis of his brachial artery as the initial manifestation of HIV infection. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10814996     DOI: 10.1002/(sici)1096-8652(200006)64:2<137::aid-ajh13>3.0.co;2-s

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

Review 1.  The procoagulant envelope virus surface: contribution to enhanced infection.

Authors:  Edward L G Pryzdial; Michael R Sutherland; Wolfram Ruf
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 2.  Current update on HIV-associated vascular disease and endothelial dysfunction.

Authors:  Hong Mu; Hong Chai; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

3.  Heart and HAART: Two sides of the coin for HIV-associated cardiology issues.

Authors:  Giuseppe Barbaro
Journal:  World J Cardiol       Date:  2010-03-26

4.  Pulmonary Embolism Mimicking Pneumonia in a HIV Patient.

Authors:  Vivek Nagaraja; Joel A Terriquez; Hemanth Gavini; Lokesh Jha; Stephen A Klotz
Journal:  Case Rep Med       Date:  2010-06-14

Review 5.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

Review 6.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Metabolic syndrome associated with HIV and highly active antiretroviral therapy.

Authors:  Giuseppe Barbaro; Gialuca Iacobellis
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

Review 8.  Human immunodeficiency virus & cardiovascular risk.

Authors:  Giuseppe Barbaro; Giorgio Barbarini
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

9.  Determinants of anemia among pregnant mothers attending antenatal care in Dessie town health facilities, northern central Ethiopia, unmatched case -control study.

Authors:  Sisay Eshete Tadesse; Omer Seid; Yemane G/Mariam; Abel Fekadu; Yitbarek Wasihun; Kedir Endris; Abebayehu Bitew
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

10.  Initial Presentation of HIV Infection With Two Successive Acute Arterial Thromboses: A Case Report.

Authors:  Bizhan Ziaian; Sam Moslemi; Maryam Tahamtan
Journal:  Iran Red Crescent Med J       Date:  2014-12-01       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.